Dr. Rishi Kakar

Psychiatry
Compass Health Systems P.A.
1065 NE 125th St Ste 206, 
North Miami, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Compass Health Systems P.A.
1065 NE 125th St Ste 206, 
North Miami, FL 

Overview

Rishi Kakar is a Psychiatrist practicing medicine in North Miami, Florida.

His clinical expertise encompasses Schizophrenia, Schizoaffective Disorder, Major Depression, and Bipolar Disorder (BPD).

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 14 clinical trials.

Specialties

Psychiatry

Licenses

Psychiatry & Neurology in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Compass Health Systems P.A.
1065 NE 125th St Ste 206, North Miami, FL 33161
Other Locations
Office
7481 W Oakland Park Blvd Ste 205, Tamarac, FL 33319

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Enrollment Status: Recruiting
Publish Date: June 15, 2026
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drug: BTRX-335140
Study Phase: Phase 2
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
Enrollment Status: Terminated
Publish Date: December 20, 2024
A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Drug
Study Drug: Endoxifen
Study Phase: Phase 3
A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Enrollment Status: Completed
Publish Date: November 01, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate the PK Profiles of LY03010 and Relative Bioavailability at Steady-state of LY03010 Versus INVEGA SUSTENNA in Schizophrenia Patients
A Study to Evaluate the PK Profiles of LY03010 and Relative Bioavailability at Steady-state of LY03010 Versus INVEGA SUSTENNA in Schizophrenia Patients
Enrollment Status: Completed
Publish Date: April 25, 2023
Intervention Type: Drug
Study Drugs: LY03010, Sustenna
Study Phase: Phase 1
A Single Arm, Adaptive Design, Pivotal Trial to Assess the Efficacy of AKL-T01, a Novel Digital Intervention Designed to Improve Attention, in Adults Diagnosed With Attention Deficit Hyperactive Disorder
A Single Arm, Adaptive Design, Pivotal Trial to Assess the Efficacy of AKL-T01, a Novel Digital Intervention Designed to Improve Attention, in Adults Diagnosed With Attention Deficit Hyperactive Disorder
Enrollment Status: Completed
Publish Date: February 28, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Enriched-Enrollment Withdrawal, Multicenter Study to Evaluate the Efficacy and Safety of a Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Subjects With Moderate to Severe Chronic Low Back Pain Currently Treated With Daily Opioids
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Enriched-Enrollment Withdrawal, Multicenter Study to Evaluate the Efficacy and Safety of a Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Subjects With Moderate to Severe Chronic Low Back Pain Currently Treated With Daily Opioids
Enrollment Status: Completed
Publish Date: October 15, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
Enrollment Status: Terminated
Publish Date: September 05, 2021
Intervention Type: Combination product
Study Drug: ABILIFY MYCITE
Study Phase: Phase 3
View 9 Less Clinical Trials

11 Total Publications

Efficacy signals in a 12-week trial of clavulanic acid to decrease cocaine use.
Efficacy signals in a 12-week trial of clavulanic acid to decrease cocaine use.
Journal: Drug and alcohol dependence
Published: December 05, 2025
Similar Doctors
Expertise in
15
conditions
Dr. Andres Kanner
Psychiatry
Expertise in
15
conditions
Dr. Andres Kanner
Psychiatry
Referral may be required

Jackson Health System

1611 NW 12th Ave, 
Miami, FL 
 (26.0 miles away)
305-243-6732
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andres Kanner is a Psychiatrist practicing medicine in Miami, Florida. Dr. Kanner is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Epilepsy, Seizures, Partial Familial Epilepsy, and Partial Seizure.

Expertise in
7
conditions
Dr. Marc Agronin
Psychiatry
Expertise in
7
conditions
Dr. Marc Agronin
Psychiatry
Referral may be required

Seasons Medical Group Of Florida PA

5200 NE 2nd Ave Fl 3, 
Miami, FL 
 (24.7 miles away)
305-514-8652
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marc Agronin is a Psychiatrist practicing medicine in Miami, Florida. Dr. Agronin is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Cerebellar Degeneration, and Lewy Body Dementia (LBD).

Expertise in
5
conditions
Dr. Emilio Mantero
Psychiatry
Expertise in
5
conditions
Dr. Emilio Mantero
Psychiatry
Referral may be required

Office

1901 SW 1st St Ste 280, 
Miami, FL 
 (27.7 miles away)
305-326-0729
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Emilio Mantero is a Psychiatrist practicing medicine in Miami, Florida. Dr. Mantero is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Schizophrenia, Seasonal Affective Disorder (SAD), Major Depression, and Schizoaffective Disorder.

Frequently Asked Questions about Dr. Rishi Kakar

How do I make an appointment with Dr. Rishi Kakar?

You can book an appointment with Dr. Rishi Kakar by calling their office at 888-852-6672. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rishi Kakar a top-rated expert for Schizophrenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rishi Kakar is classified as an Experienced expert for Schizophrenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rishi Kakar specialize in?

While Dr. Rishi Kakar is a Psychiatry, they have specific expertise in Schizophrenia, Schizoaffective Disorder, and Major Depression. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Psychiatry.

Does Dr. Rishi Kakar participate in research or clinical trials?

Yes. Dr. Rishi Kakar has published 11 articles and abstracts on conditions like Schizophrenia. You can view a list of Dr. Rishi Kakar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rishi Kakar accept my insurance?

Dr. Rishi Kakar accepts most major insurance plans, including Cigna and Florida Blue. We recommend calling the office directly at 888-852-6672 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kakar's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile